GlobeNewswire·Apr 30, 2026, 9:00 AM ET

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

Fate Therapeutics, Inc. will present clinical data for its off-the-shelf CAR T-cell candidate FT819 at the Congress of Clinical Rheumatology – East meeting in Destin, FL, from April 30 to May 3, 2026.
The company will participate in a Poster Rounding Session on Friday, May 1, 2026, featuring an encore presentation of Phase 1 trial data from the systemic lupus erythematosus (SLE) study arm.
The presentation includes safety, efficacy, & translational data from 13 SLE patients with a data cutoff of December 23, 2025.
Highlights from the first 10 SLE patients treated with Regimen A show clinically meaningful improvements following a single dose of FT819 combined with fludarabine-free conditioning chemotherapy.
Observed response metrics at Month 6 include a 13-point decrease in SLEDAI-2K scores, a 1.75-point decrease in PGA scores, & significant reductions in UPCr levels at Months 3 & 6.
Patient-reported outcomes showed FACIT-Fatigue score improvements of 23.4 points at Month 3 & 24.3 points at Month 6.
The poster title is "Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy with Reduced Conditioning in SLE: A Phase 1 Study."
Fate Therapeutics is a San Diego-based clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies for cancer & autoimmune diseases.